Our most-read articles explore “occlusion MI” versus STEMI, TAVI in asymptomatic AS, and highlights from recent conferences.

The lower rate of net adverse clinical events was driven by less bleeding in those on 1 month of prasugrel-based DAPT.

Researchers say the data further support the use of an FFR-first strategy in treating intermediate coronary lesions.

The findings hint at why the ABYSS trial failed to show it was safe to stop beta-blockers after an MI in stable patients.

Based on these numbers, the researchers estimated that 5-year cumulative risks of recurrent events were 17.4% for ischemic ...

Relying on iFR/FFR values from the LCx alone could mean many patients with left main disease miss out on revascularization.

The explanation for why the valve failed is too little, too late: Boston Scientific ended global sales of the device ...

The approval is tightly defined: the system will be for patients ineligible for surgery and with anatomy unfavorable for TEER ...

HELSINKI, Finland—It may be possible to safely cut back on the level of monitoring performed in select patients with acute ...

OCT seems to reduce periprocedural MI, a benefit not seen in the chronic coronary syndrome patients that deserves further ...

In the ILIAS ANOCA trial, using CFT to guide treatment according to ANOCA endotype led to larger QoL gains over 6 months.

Citing a low hemorrhage rate and other issues, one expert says the results should be replicated before changing practice.